336 related articles for article (PubMed ID: 26792032)
1. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
Berger BM; Schroy PC; Dinh TA
Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
5. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
Prince M; Lester L; Chiniwala R; Berger B
World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
[TBL] [Abstract][Full Text] [Related]
6. Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
Finney Rutten LJ; Jacobson RM; Wilson PM; Jacobson DJ; Fan C; Kisiel JB; Sweetser S; Tulledge-Scheitel SM; St Sauver JL
Mayo Clin Proc; 2017 May; 92(5):726-733. PubMed ID: 28473037
[TBL] [Abstract][Full Text] [Related]
7. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
9. A novel multitarget stool DNA test for colorectal cancer screening.
Malik P
Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807
[TBL] [Abstract][Full Text] [Related]
10. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
11. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
[TBL] [Abstract][Full Text] [Related]
12. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
Pickhardt PJ; Correale L; Hassan C
AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
[No Abstract] [Full Text] [Related]
13. Colorectal Neoplasia Detection in Individuals With Positive Multitarget Stool DNA Tests: Data From the New Hampshire Colonoscopy Registry.
Anderson JC; Robinson CM; Hisey WM; Edwards DK; Kneedler BL; Berger BM; Butterly LF
J Clin Gastroenterol; 2022 May-Jun 01; 56(5):419-425. PubMed ID: 33973962
[TBL] [Abstract][Full Text] [Related]
14. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.
Bosch LJW; Melotte V; Mongera S; Daenen KLJ; Coupé VMH; van Turenhout ST; Stoop EM; de Wijkerslooth TR; Mulder CJJ; Rausch C; Kuipers EJ; Dekker E; Domanico MJ; Lidgard GP; Berger BM; van Engeland M; Carvalho B; Meijer GA
Am J Gastroenterol; 2019 Dec; 114(12):1909-1918. PubMed ID: 31764091
[TBL] [Abstract][Full Text] [Related]
15. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
[No Abstract] [Full Text] [Related]
16. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
[No Abstract] [Full Text] [Related]
17. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
18. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of Multitarget Stool DNA and CT Colonography for Noninvasive Colorectal Cancer Screening.
Pickhardt PJ; Graffy PM; Weigman B; Deiss-Yehiely N; Hassan C; Weiss JM
Radiology; 2020 Oct; 297(1):120-129. PubMed ID: 32779997
[TBL] [Abstract][Full Text] [Related]
20. Multitarget Stool DNA Testing Has High Positive Predictive Value for Colorectal Neoplasia on the Second Round of Testing.
Voss JK; Ebner DW; Burger KN; Mahoney DW; Devens ME; Lowrie KL; Kisiel JB
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2399-2406. PubMed ID: 36621751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]